Dear Authors,
If you believe that your paper was mistakenly rejected by other leading journals and you do not agree with final decision, the editors of Reports of Practical Oncology and Radiotherapy offer new fast track review. You may submit your manuscript to Reports of Practical Oncology and Radiotherapy together with all prior peer-reviews obtained from the other journal and your rebuttal letter. We guarantee review based decision within 72 hours from the time we will receive your manuscript.

Fast track submission process: Please submit the manuscript with all reviews and rebuttal letter by email to Dr. Michal Masternak ( for fast review processing. To assure immediate attention the email title must to include: RPOR-fast track- Last Name First Name (of corresponding author).

Volume 6, Number 1, 2001

The analysis of doses in the tumour and in critical tissues in the brachytherapy of malignant melanoma localised in eyes.

Kierzkowski J, Malicki J, Roszak A.


Brachytherapy is known and used procedure in the treatment of tumours localised in eyes, especially recommended when avoiding of enucleation accompany the long term cure.

Aim: The aim of this paper was to compare the doses delivered to the tumour and critical tissues during the treatment of the group of patients treated with Ru-106 applicator.

Patients: Between 1994 and 2000, 67 patients (dgn. melanoma malignum in eye) underwent brachytherapy. At 51 patients the tumour was localized in the back of eye, at 15 equatorially and at one in the front section of the eyeball. The median of the patients' age was 56.3 years. The CCB type applicator was applied for 56 patients, the COB for 7 and the ROA for 4 patients.

Method: Irradiation - Prescribed dose of 60 Gy was normalized to the top of the tumour, it decreased by 50%--10% per millimetre with the distance from applicator. The isotope producer determined the dose-rate accuracy for +/-30%. This caused that therapeutic dose had to be calculated taking account for the minimal dose-rate, while the doses in critical organs for maximal dose-rate possible.

Analysis: All patients were divided into three subgroups: 8 patients into 1st , 19 into 2nd and 40 into 3rd. The inclusion criterion was size of tumour: up to 3 mm of height (1st group), 3-5 mm (2nd), and larger than 5 mm (3rd) respectively.

Results: Table presents mean doses in the tumour, sclera and lens (calculated at it's middle) for each group of patients.
Conclusions: Mean doses in tumour varied from 102.9 Gy to 268.2 Gy depending on the tumour size. Doses in sclera and lens did not exceed the tolerance levels in all three groups of patients.

Signature: Rep Pract Oncol Radiother, 2001; 6(1) : 31-32

« back


Indexed in: EMBASE®, the Excerpta Medica database, the Elsevier BIOBASE (Current Awareness in Biological Sciences) and in the Index Copernicus.